<DOC>
	<DOCNO>NCT02179528</DOCNO>
	<brief_summary>Patients extensive-stage small cell lung cancer receive six cycle chemotherapy ( etoposide plus platinum ) first-line treatment , achieve Complete Response ( CR ) /Partial Response ( PR ) accept small dos etoposide maintenance treatment . The objective study evaluate progression free survival , overall survival , objective response rate , disease control rate safety etoposide maintenance therapy . Based previous study maintenance therapy small cell lung cancer , hypothesis study maintenance therapy use etoposide may improve progression free survival , overall survival select patient . The investigator use peripheral blood ass circulate tumor cell cell-free DNA , may help u screen subgroup patient well response etoposide maintenance therapy .</brief_summary>
	<brief_title>Study Small Doses Etoposide Maintenance Treatment Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>Pathological diagnosis small cell lung cancer Extensive stage accord American Veteran Staging System At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) score performance status 0 2 Age≥18 year Adequate organ function Consent form accord Guideline Good Clinical Practice International Conference Harmonisation ( ICHGCP ) guideline The expected survival≥2 month Pathological diagnosis mix small cell lung cancer Limited stage accord American Veteran Staging System Other preexist exist malignant tumor , include nonmelanoma skin cancer effective treatment , cervical cancer situ tumor response 3 year consider cured investigator Known preexist interstitial lung disease Preexisting uncontrolled gastrointestinal disease may affect drug absorption worsen exist disease believe investigator Any medical history coexist disease may affect compliance patient assessment safety effectiveness drug believe investigator Pregnant lactate woman Active phase hepatitis B virus infection , Active phase hepatitis C virus infection know HIV carrier</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>